From recurrence monitoring to treatment response: MRD data insights across the cancer care continuum
This session will explore how minimal residual disease (MRD) data provides critical insights across the cancer care continuum.
May 11, 2026
SESSION HIGHLIGHTS
Learn the fundamental principles of MRD testing and its significance in precision medicine.
Understand the differences between tumor-informed and tumor-naive MRD testing methodologies.
Discover how key performance factors like sensitivity and specificity influence clinical utility and risk stratification.
Hear real-world clinical cases on how MRD testing can be used to inform treatment decisions, including surveillance and IO treatment response monitoring.
Conference
Webinar
